Clinically assisted hydration at the end of life - yes, no, maybe?

Hydration evidence remains limited

Physiological fluid losses continue near death, but end-of-life changes remain uncertain. Evidence is limited: few small randomized trials exist, and earlier studies often use 1 L/day despite clinical dehydration, which may be insufficient to replace prior and ongoing losses.

Chelsea 2 shows mixed outcomes

In hydrated patients with prognosis under one week, clinically assisted hydration shows no difference in delirium, sedation, pain, dyspnea, nausea, vomiting, edema, pulmonary edema, or ascites; survival increases, while upper airway secretions and anticholinergic use increase.

Individualized decisions are indicated

The findings do not support routine use or routine withholding of clinically assisted hydration. Decisions are individualized according to patient circumstances and preferences; in cases of uncertainty or disagreement, a time-limited trial with explicit continuation and stopping criteria is appropriate.

In the educational session “Clinically assisted hydration at the end of life - yes, no, maybe?”, organized by Klinik Barmelweid, Prof. Dr. Andrew Davies discusses the physiological rationale, ethical controversy, and limited evidence base surrounding clinically assisted hydration in dying patients. He emphasizes that fluid loss continues at the end of life despite altered physiology, while current literature remains inconsistent and randomized evidence is sparse, methodologically heterogeneous, and often based on inadequate fluid volumes. Prof. Dr. Davies presents the Chelsea 2 cluster-randomized trial, which includes 1,565 predominantly older patients with an estimated prognosis of less than one week and compares standard end-of-life care with or without weight-based clinically assisted hydration. The reported headline results show no difference between groups in delirium, sedation, pain, dyspnea, nausea and vomiting, peripheral edema, pulmonary edema, or ascites, but they do show improved survival in the hydration group and a higher prevalence of upper airway secretions with increased anticholinergic use. He interprets these findings as evidence that clinically assisted hydration is generally safe when appropriately managed, while acknowledging that any survival benefit may be viewed differently depending on individual goals of care and symptom burden. Prof. Dr. Davies therefore argues against both routine administration and blanket withholding of fluids, and instead supports individualized decision-making guided by patient circumstances, clinical indications or contraindications, and patient preferences. He further notes that persistent thirst should not be reduced to oral care alone and refers to MASCC guidance, which recommends a time-limited trial of hydration with explicit criteria for continuation or discontinuation when uncertainty or disagreement exists.